Gilteritinib monotherapy as a transplant bridging option for high risk FLT3-mutated AML with t(6;9)(p23;q34.1);DEK-NUP214 in morphological but not cytogenetic or molecular remission following standard induction chemotherapy

We report a case of FLT3-mutated AML with t(6;9) in which induction chemotherapy with DA and midostaurin failed to achieve complete cytogenetic or molecular remission. Due to the COVID-19 pandemic and co-existing cellulitis, monotherapy with the selective FLT3-inhibitor gilteritinib was used as an a...

Descripción completa

Detalles Bibliográficos
Autores principales: Day, James W, Fox, Thomas A, Gupta, Rajeev, Khwaja, Asim, Wilson, Andrew J, Kottaridis, Panagiotis D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8844896/
https://www.ncbi.nlm.nih.gov/pubmed/35198371
http://dx.doi.org/10.1016/j.lrr.2022.100291
_version_ 1784651564911165440
author Day, James W
Fox, Thomas A
Gupta, Rajeev
Khwaja, Asim
Wilson, Andrew J
Kottaridis, Panagiotis D
author_facet Day, James W
Fox, Thomas A
Gupta, Rajeev
Khwaja, Asim
Wilson, Andrew J
Kottaridis, Panagiotis D
author_sort Day, James W
collection PubMed
description We report a case of FLT3-mutated AML with t(6;9) in which induction chemotherapy with DA and midostaurin failed to achieve complete cytogenetic or molecular remission. Due to the COVID-19 pandemic and co-existing cellulitis, monotherapy with the selective FLT3-inhibitor gilteritinib was used as an alternative consolidation treatment option rather than further intensive chemotherapy. Gilteritinib was able to achieve complete molecular and cytogenetic remission despite the additional cytogenetic abnormality. This case provides supporting evidence for the use of single agent gilteritinib in high-risk primary refractory FLT3-mutated AML with t(6;9) prior to transplantation.
format Online
Article
Text
id pubmed-8844896
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-88448962022-02-22 Gilteritinib monotherapy as a transplant bridging option for high risk FLT3-mutated AML with t(6;9)(p23;q34.1);DEK-NUP214 in morphological but not cytogenetic or molecular remission following standard induction chemotherapy Day, James W Fox, Thomas A Gupta, Rajeev Khwaja, Asim Wilson, Andrew J Kottaridis, Panagiotis D Leuk Res Rep Article We report a case of FLT3-mutated AML with t(6;9) in which induction chemotherapy with DA and midostaurin failed to achieve complete cytogenetic or molecular remission. Due to the COVID-19 pandemic and co-existing cellulitis, monotherapy with the selective FLT3-inhibitor gilteritinib was used as an alternative consolidation treatment option rather than further intensive chemotherapy. Gilteritinib was able to achieve complete molecular and cytogenetic remission despite the additional cytogenetic abnormality. This case provides supporting evidence for the use of single agent gilteritinib in high-risk primary refractory FLT3-mutated AML with t(6;9) prior to transplantation. Elsevier 2022-02-07 /pmc/articles/PMC8844896/ /pubmed/35198371 http://dx.doi.org/10.1016/j.lrr.2022.100291 Text en © 2022 Published by Elsevier Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Day, James W
Fox, Thomas A
Gupta, Rajeev
Khwaja, Asim
Wilson, Andrew J
Kottaridis, Panagiotis D
Gilteritinib monotherapy as a transplant bridging option for high risk FLT3-mutated AML with t(6;9)(p23;q34.1);DEK-NUP214 in morphological but not cytogenetic or molecular remission following standard induction chemotherapy
title Gilteritinib monotherapy as a transplant bridging option for high risk FLT3-mutated AML with t(6;9)(p23;q34.1);DEK-NUP214 in morphological but not cytogenetic or molecular remission following standard induction chemotherapy
title_full Gilteritinib monotherapy as a transplant bridging option for high risk FLT3-mutated AML with t(6;9)(p23;q34.1);DEK-NUP214 in morphological but not cytogenetic or molecular remission following standard induction chemotherapy
title_fullStr Gilteritinib monotherapy as a transplant bridging option for high risk FLT3-mutated AML with t(6;9)(p23;q34.1);DEK-NUP214 in morphological but not cytogenetic or molecular remission following standard induction chemotherapy
title_full_unstemmed Gilteritinib monotherapy as a transplant bridging option for high risk FLT3-mutated AML with t(6;9)(p23;q34.1);DEK-NUP214 in morphological but not cytogenetic or molecular remission following standard induction chemotherapy
title_short Gilteritinib monotherapy as a transplant bridging option for high risk FLT3-mutated AML with t(6;9)(p23;q34.1);DEK-NUP214 in morphological but not cytogenetic or molecular remission following standard induction chemotherapy
title_sort gilteritinib monotherapy as a transplant bridging option for high risk flt3-mutated aml with t(6;9)(p23;q34.1);dek-nup214 in morphological but not cytogenetic or molecular remission following standard induction chemotherapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8844896/
https://www.ncbi.nlm.nih.gov/pubmed/35198371
http://dx.doi.org/10.1016/j.lrr.2022.100291
work_keys_str_mv AT dayjamesw gilteritinibmonotherapyasatransplantbridgingoptionforhighriskflt3mutatedamlwitht69p23q341deknup214inmorphologicalbutnotcytogeneticormolecularremissionfollowingstandardinductionchemotherapy
AT foxthomasa gilteritinibmonotherapyasatransplantbridgingoptionforhighriskflt3mutatedamlwitht69p23q341deknup214inmorphologicalbutnotcytogeneticormolecularremissionfollowingstandardinductionchemotherapy
AT guptarajeev gilteritinibmonotherapyasatransplantbridgingoptionforhighriskflt3mutatedamlwitht69p23q341deknup214inmorphologicalbutnotcytogeneticormolecularremissionfollowingstandardinductionchemotherapy
AT khwajaasim gilteritinibmonotherapyasatransplantbridgingoptionforhighriskflt3mutatedamlwitht69p23q341deknup214inmorphologicalbutnotcytogeneticormolecularremissionfollowingstandardinductionchemotherapy
AT wilsonandrewj gilteritinibmonotherapyasatransplantbridgingoptionforhighriskflt3mutatedamlwitht69p23q341deknup214inmorphologicalbutnotcytogeneticormolecularremissionfollowingstandardinductionchemotherapy
AT kottaridispanagiotisd gilteritinibmonotherapyasatransplantbridgingoptionforhighriskflt3mutatedamlwitht69p23q341deknup214inmorphologicalbutnotcytogeneticormolecularremissionfollowingstandardinductionchemotherapy

Ejemplares similares